| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 353.2 | 120.7 |
| Profit before tax | -59.3 | -186.5 |
| Net income | -56.7 | -182.7 |
| EPS (diluted, $ a share) | $-0.42 | $-0.95 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +192.6% |
|---|---|
| Operating margin | -3.3% |
10-Q filed with the SEC, NASDAQ: BBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
BridgeBio Pharma, Inc.: key numbers
- Share price
- $77.36Close, Nov 16
- Market cap
- $15.1B
- Shares outstanding
- 194.8MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BridgeBio Pharma, Inc.
All →BridgeBio Pharma CAO Maricel Apuli Sells $146K of Stock
Maricel Apuli, CAO, sold 2,000 shares of BridgeBio Pharma, Inc. at $72.85 a share, worth $146K in total on Oct 30, 2026. Shares held after the trade: 120,687 (-1.6%).
- Value
- $146K
- Shares
- 2,000
- Price
- $72.85
- Role
- CAO
- Holding change
- -1.6%
- Trade date
- Oct 30, 2026
BridgeBio Pharma Earnings Call: Key Takeaways
BridgeBio is transitioning to a multi-product commercial stage company with $253.2M in Acaramidus revenue and three major FDA PDUFA dates scheduled within the next seven months.
- Call
- Oct 29, 2026, 4:30 PM ET
BridgeBio Pharma Financial Results
BridgeBio Pharma reported Q3 2026 financial results, highlighted by $353.2 million in total revenue, including $253.2 million from U.S. Attruby net product sales. The company is preparing for three potential product launches in 2026 and 2027 for BBP-418, oral infigratinib, and encaleret, all of which have been granted Priority Review by the FDA.
- Term
- Q3 2026
BridgeBio Pharma Business Update
BridgeBio Pharma announced that the FDA has accepted its New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia and granted it Priority Review. The FDA has assigned a PDUFA target action date of February 4, 2027, for the potential approval of what would be the first oral therapy for this condition. The filing is supported by Phase 3 PROPEL 3 data showing significant improvements in annualized height velocity and body proportionality.
- Counterparty
- FDA
BridgeBio Pharma CEO Neil Kumar Sells $691K of Stock
Neil Kumar, CEO, sold 10,000 shares of BridgeBio Pharma, Inc. at $69.01 to $69.57 a share (average $69.08) in 2 transactions, worth $691K in total on Sep 17, 2026. Shares held after the trade: 495,686 (-0.3%).
- Value
- $691K
- Shares
- 10,000
- Average price
- $69.08
- Role
- CEO
- Holding change
- -0.3%
- Trade date
- Sep 17, 2026